Evercore ISI initiated coverage of West Pharmaceutical (WST) with an Outperform rating and $275 price target The bull thesis on the stock is tied to mix shift in high value components which primarily serves the biologics market where West Pharmaceutical has a roughly 90% participation rate, the analyst tells investors in a research note. Fundamentals in the biologics market are strong, enabling significant margin accretion, the firm added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue